HMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal Adenocarcinoma

Yamamoto, Naomi; Dobersch, Stephanie; M. Loveless, Ian; N. Samraj, Annie; Ho Jang, Gun; Haraguchi, Miki; Kang, Liang‐I; B. Ruzinova, Marianna; Vij, Kiran; L. Mudd, Jacqueline; Walsh, Thomas; A. Safyan, Rachael; Gabriela Chiorean, E.; R. Hingorani, Sunil; M. Bolton, Nathan; Li, Li; C. Fields, Ryan; G. DeNardo, David; Notta, Faiyaz; C. Crawford, Howard; G. Steele, Nina; Kugel, Sita

doi:10.1158/1078-0432.ccr-24-2200

Public

HMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal Adenocarcinoma

Published in Clinical Cancer Research • Dec 16, 2024

Authors:

Naomi Yamamoto

Stephanie Dobersch

Ian M. Loveless

Abstract

PURPOSE: The purpose of this study was to establish HMGA2 as a marker of basal-like disease in pancreatic ductal adenocarcinoma (PDAC) and explore its use as a biomarker for prognosis and treatment resistance. EXPERIMENTAL DESIGN: We identified high-mobility group A2 (HMGA2) protein expression in ba...

Subject

Gemcitabine

HMGA2

Pancreatic cancer

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!